


PENDING**(IN202311064593)**

Liposomal formulations of decitabine for leukemia treatment and methods thereof



NEED

Leukemia treatments often involve harsh side effects due to non-targeted drug delivery. Current therapies lack specificity, causing toxicity and limiting effectiveness. A more efficient, targeted approach could revolutionize treatment by minimizing adverse effects.

TECHNOLOGY OVERVIEW

This patent presents a surface-modified liposome formulation designed for leukemia treatment. It encapsulates a nucleic acid synthesis inhibitor, such as decitabine, within liposomes, improving targeted drug delivery. The liposomes are optimized through a specific preparation process, offering better drug stability, controlled release, and reduced side effects.

TECHNOLOGY KEY FEATURES

Surface-modified liposomes, optimized drug delivery, liposome size (100–200 nm), encapsulating decitabine, improved targeting, controlled release, enhanced therapeutic efficiency, reduced toxicity, formulation via thin-film hydration, cryoprotectant lyophilization.

[Read more here](#)

MARKET ANALYSIS

Global market for liposomal drug delivery systems is growing at a CAGR of 10.2%, expected to reach \$15.9 billion by 2033 (source: Allied Market Research, 2023). Indian pharmaceutical market for cancer therapeutics is expected to grow at 12.5% CAGR through 2030 (source: IMARC Group, 2024).

Target Industries

- , Liposomal drug developers, oncology pharmaceutical manufacturers, biopharmaceutical companies specializing in nanomedicine, and drug formulation service providers.
- , Drug delivery system integrators, liposome formulation research platforms, specialized pharmaceutical companies focusing on targeted cancer therapies, clinical R&D labs.

AT A GLANCE

- SDG 3 (Good Health and Well-being), SDG 9 (Industry, Innovation, and Infrastructure)

Technology is available for licensing/ co-development.

Reach out to Prof. Deepak Chitkara, Coordinator, BITS Technology Enabling Centre,
BITS Pilani Contact Details: tec.bits@pilani.bits-pilani.ac.in, 91 1596-255913